Mechanism and Potential Therapy in Ameloblastoma: Akt Signaling Pathway
Abstract
BACKGROUND: Ameloblastoma is the most common benign aggressive tumor. They are more prevalent in the mandible than in the maxilla, mostly observed on the posterior of the jaw. Ameloblastoma can arise at any age, however it most usually affect patients between the ages of 20 and 40. Numerous efforts have been made to develop molecular targeted therapies to treat cancers, such as Akt inhibitors. However, these drugs have not been tested for treating ameloblastoma yet, since underlying molecular factors have yet to be identified. This study was carried out to delineate possible molecular mechanisms related to the Akt signaling pathway in ameloblastoma and potential drugs for ameloblastoma treatment.
CONTENT: Akt signaling pathway in ameloblastoma has been implicated in the formation and progression of tumors. Akt signaling is involved in various cellular mechanisms, such as cell cycle, apoptosis, and cytoskeletal rearrangement, which includes Phosphatidyl Inositol 3 Kinase (PI3K)-Akt signaling, Akt-Nuclear Factor (NF)-κB signaling, Akt-Mammalian Target of Rapamycin (mTOR) signaling, Akt-B-cell Lymphoma (Bcl)-2 Family signaling, Akt-Survivin signaling. Potential ways of treatments using chemical compounds and micro RNA (miRNA), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) were explored as well.
SUMMARY: The present review highlights various Akt signaling involved in ameloblastoma and its potential pathways for treatments, while the gold standard of ameloblastoma treatment is still surgery to remove the tumor, there are many potential agents through various means of inhibition for ameloblastoma. Therefore, understanding the underlying signaling on ameloblastoma is necessary to induce inhibition on ameloblastoma. More research in potential ways to inhibit Akt signaling in ameloblastoma will lead to a better management of ameloblastoma in the future.
KEYWORDS: ameloblastoma, Akt, PI3K, NFkB, mTOR, Bcl-2, miRNA, CRISPR
Full Text:
PDFReferences
Payne S, Albert T, Lighthall J. Management of ameloblastoma in the pediatric population. Oper Tech Otolaryngol Head Neck Surg. 2015; 26(3): 1–13, CrossRef.
Fahradyan A, Odono L, Hammoudeh JA, Howell LK. Ameloblastic carcinoma in situ: review of literature and a case presentation in a pediatric patient. Cleft Palate Craniofac J. 2019; 56(1): 94–100, CrossRef.
Oomens MAEM, van der Waal I. Epidemiology of ameloblastomas of the jaws; a report from the Netherlands. Med Oral Patol Oral Cir Bucal. 2014; 19(6): e581–3, CrossRef.
Fuchigami T, Ono Y, Kishida S, Nakamura N. Molecular biological findings of ameloblastoma. Jpn Dent Sci Rev. 2021; 57: 27–32, CrossRef.
Brown NA, Betz BL. Ameloblastoma: a review of recent molecular pathogenetic discoveries. Biomark Cancer. 2015; 7(Suppl 2): 19–24, CrossRef.
Cecim RL, Carmo HAF, Kataoka MSS, Freitas VM, de Melo Alves Júnior S, Pedreira EN, et al. Expression of molecules related to AKT pathway as putative regulators of ameloblastoma local invasiveness. J Oral Pathol Med. 2014; 43(2): 143–7, CrossRef.
Li N, Sui J, Liu H, Zhong M, Zhang M, Wang Y, et al. Expression of phosphorylated Akt/mTOR and clinical significance in human ameloblastoma. Int J Clin Exp Med. 2015; 8(4): 5236–44, PMID.
Sandra F, Hendarmin L, Nakao Y, Nakamura N, Nakamura S. Inhibition of Akt and MAPK pathways elevated potential of TNFα in inducing apoptosis in ameloblastoma. Oral Oncology. 2006; 1(42): 38–44, CrossRef.
Nair A, Chauhan P, Saha B, Kubatzky KF. Conceptual evolution of cell signaling. Int J Mol Sci. 2019; 20(13): E3292, CrossRef.
Vogel C, Bashton M, Kerrison ND, Chothia C, Teichmann SA. Structure, function and evolution of multidomain proteins. Curr Opin Struct Biol. 2004; 14(2): 208–16, CrossRef.
Sandra F, Harada H, Nakamura N, Ohishi M. Midkine induced growth of ameloblastoma through MAPK and Akt pathways. Oral Oncol. 2004; 40(3): 274–80, CrossRef.
Gough NR. Neuroprotective mitochondrial glutamate receptors. science signaling. 2012; 5(247): ec272, CrossRef.
Gao J, Wang Y, Cai M, Pan Y, Xu H, Jiang J, et al. Mechanistic insights into EGFR membrane clustering revealed by super-resolution imaging. Nanoscale. 2015; 7(6): 2511–9, CrossRef.
Park WS, Heo WD, Whalen JH, O’Rourke NA, Bryan HM, Meyer T, et al. Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. Mol Cell. 2008; 30(3): 381–92, CrossRef.
Dermody TS, Kirchner E, Guglielmi KM, Stehle T. Immunoglobulin superfamily virus receptors and the evolution of adaptive immunity. PLoS Pathog. 2009; 5(11): e1000481, CrossRef.
Harsha C, Banik K, Ang HL, Girisa S, Vikkurthi R, Parama D, et al. Targeting AKT/mTOR in oral cancer: mechanisms and advances in clinical trials. Int J Mol Sci. 2020; 21(9): 3285, CrossRef.
Shi X, Wang J, Lei Y, Cong C, Tan D, Zhou X. Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review). Mol Med Rep. 2019; 19(6): 4529–35, CrossRef.
Urs PAB, Singh DH, Verma PM. Genetic polymorphism and gene expression of PI3K gene in ameloblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 128(1): e89, CrossRef.
Sivakumar M, Yoithapprabhunath TR, Nirmal RM, Veeravarmal V, Dineshshankar J, Amsaveni R. Immunohistochemical analysis of Nuclear Factor-kappa B (NF-κB) between follicular and plexiform ameloblastomas: A pilot study. J Oral Maxillofac Pathol. 2020; 24(3): 466–71, CrossRef.
Sandra F, Nakamura N, Mitsuyasu T, Shiratsuchi Y, Ohishi M. Two relatively distinct patterns of ameloblastoma: an anti-apoptotic proliferating site in the outer layer (periphery) and a pro-apoptotic differentiating site in the inner layer (centre). Histopathology. 2001; 39(1): 93–8, CrossRef.
Sandra F, Hendarmin L, Nakao Y, Nakamura N, Nakamura S. TRAIL cleaves caspase-8, -9 and -3 of AM-1 cells: A possible pathway for TRAIL to induce apoptosis in ameloblastoma. Oncodev Biol Med. 2005; 26(5): 258–64, CrossRef.
Chu N, Viennet T, Bae H, Salguero A, Boeszoermenyi A, Arthanari H, et al. The structural determinants of PH domain-mediated regulation of Akt revealed by segmental labeling. Elife. 2020; 9: e59151, CrossRef.
Zhang P, Chen XB, Ding BQ, Liu HL, He T. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway. Biosci Rep. 2018; 38(6): BSR20181711, CrossRef.
Xu S, Yang Z, Jin P, Yang X, Li X, Wei X, et al. Metformin suppresses tumor progression by inactivating stromal fibroblasts in ovarian cancer. Mol Cancer Ther. 2018; 17(6): 1291–302, CrossRef.
Eberle J. Countering TRAIL resistance in melanoma. Cancers. 2019; 11(5): 656, CrossRef.
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020; 11(9): 1–12, CrossRef.
Zhu DD, Zhang J, Deng W, Yip YL, Lung HL, Tsang CM, et al. Significance of NF-κB activation in immortalization of nasopharyngeal epithelial cells. Int J Cancer. 2016; 138(5): 1175–85, CrossRef.
Zhang L, Chen XM, Sun ZJ, Bian Z, Fan MW, Chen Z. Epithelial expression of SHH signaling pathway in odontogenic tumors. Oral Oncol. 2006; 42(4): 398–408, CrossRef.
Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-κB: a blossoming of relevance to human pathobiology. Cell. 2017; 168(1–2): 37–57, CrossRef.
Jackson J, Halim J, Anggraeni R, Sandra F. Bone resorption in ameloblastoma and its underlying mechanism. Indones J Cancer Chemoprev. 2021; 12(1): 57–66, CrossRef.
Sandra F, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol. 2006; 42(4): 415–20, CrossRef.
Sandra F, Hendarmin L, Kukita T, Nakao Y, Nakamura N, Nakamura S. Ameloblastoma induces osteoclastogenesis: A possible role of ameloblastoma in expanding in the bone. Oral Oncol. 2005; 41(6): 637–44, CrossRef.
Hendarmin L, Kawano S, Yoshiga D, Sandra F, Mitsuyasu T, Nakao Y, et al. An anti-apoptotic role of NF-κB in TNFα-induced apoptosis in an ameloblastoma cell line. Oral Sci Int. 2008; 5(2): 96–103, CrossRef.
Sauk JJ, Nikitakis NG, Scheper MA. Are we on the brink of nonsurgical treatment for ameloblastoma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110(1): 68–78, CrossRef.
Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 2013; 22(4): 641–64, CrossRef.
Shanmugam MK, Warrier S, Kumar AP, Sethi G, Arfuso F. Potential role of natural compounds as anti-angiogenic agents in cancer. Curr Vasc Pharmacol. 2017; 15(6): 503–19, CrossRef.
Siar CH, Ng KH. Epithelial-to-mesenchymal transition in ameloblastoma: focus on morphologically evident mesenchymal phenotypic transition. Pathology. 2019; 51(5): 494–501, CrossRef.
Qi Y, Liu J, Chao J, Scheuerman MP, Rahimi SA, Lee LY, et al. PTEN suppresses epithelial–mesenchymal transition and cancer stem cell activity by downregulating Abi1. Sci Rep. 2020; 10(1):12685, CrossRef.
Lapthanasupkul P, Klongnoi B, Mutirangura A, Kitkumthorn N. Investigation of PTEN promoter methylation in ameloblastoma. Med Oral Patol Oral Cir Bucal. 2020; 25(4): e481–7, CrossRef.
Sandra F. Targeting ameloblatoma into apoptosis. Indones Biomed J. 2018; 10(1): 35–9, CrossRef.
Sindura C, Babu C, Mysorekar V, Kumar V. Study of immunohistochemical demonstration of Bcl-2 protein in ameloblastoma and keratocystic odontogenic tumor. J Oral Maxillofac Pathol. 2013; 17(2): 176–80, CrossRef.
González-González R, Molina-Frechero N, Damian-Matsumura P, Salazar-Rodriguez S, Bologna-Molina R. Immunohistochemical expression of survivin and its relationship with cell apoptosis and proliferation in ameloblastomas. Disease Markers. 2015; 2015: e301781, CrossRef.
Soluk Tekkeşin M, Mutlu Güner S, Olgac V. Expressions of bax, bcl-2 and Ki-67 in odontogenic keratocysts (keratocystic odontogenic tumor) in comparison with ameloblastomas and radicular cysts. Turk Patoloji Derg. 2012; 28(1): 49–55, CrossRef.
Kim JY, Kim J, Bazarsad S, Cha IH, Cho SW, Kim J. Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas. Oral Diseases. 2019; 25(4): 1158–68, CrossRef.
Garcia PB, Attardi LD. Illuminating p53 function in cancer with genetically engineered mouse models. Semin Cell Dev Biol. 2014; 27: 74–85, CrossRef.
Shaikh Z, Niranjan KC. Cell cycle aberration in ameloblastoma and adenomatoid odontogenic tumor: As evidenced by the expression of p53 and survivin. Indian J Dent Res. 2015; 26(6): 565–70, CrossRef.
Nagi R, Sahu S, Rakesh N. Molecular and genetic aspects in the etiopathogenesis of ameloblastoma: An update. J Oral Maxillofac Pathol. 2016; 20(3): 497–504, CrossRef.
Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18(1): 26, CrossRef.
Abliz A, Deng W, Sun R, Guo W, Zhao L, Wang W. Wortmannin, PI3K/Akt signaling pathway inhibitor, attenuates thyroid injury associated with severe acute pancreatitis in rats. Int J Clin Exp Pathol. 2015; 8(11): 13821–33, PMID.
Wang Y, Kuramitsu Y, Baron B, Kitagawa T, Tokuda K, Akada J, et al. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol. 2017; 50(2): 606–12, CrossRef.
Singh AR, Joshi S, George E, Durden DL. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in 12 V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014; 14(1): 105, CrossRef.
Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012; 8(5): 623–33, CrossRef.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019; 21(1): 78, CrossRef.
Ren C, Chen H, Han C, Fu D, Zhou L, Jin G, et al. miR-486-5p expression pattern in esophageal squamous cell carcinoma, gastric cancer and its prognostic value. Oncotarget. 2016; 7(13): 15840–53, CrossRef.
Shi Y, Li Y, Wu W, Xu B, Ju J. MiR-181d functions as a potential tumor suppressor in oral squamous cell carcinoma by targeting K-ras. Int J Clin Exp Pathol. 2017; 10(7): 7847–55, PMID.
Jiang K, Xie LF, Xiao TZ, Qiu MY, Wang WL. MiR-181d inhibits cell proliferation and metastasis through PI3K/AKT pathway in gastric cancer. Eur Rev Med Pharmacol Sci. 2019; 23(20): 8861–9, CrossRef.
Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012; 44(4): 237–44, CrossRef.
Kwon JJ, Factora TD, Dey S, Kota J. A systematic review of miR-29 in cancer. Mol Ther Oncolytics. 2019; 12: 173–94, CrossRef.
Teng Y, Zhang Y, Qu K, Yang X, Fu J, Chen W, et al. MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3. Oncotarget. 2015; 6(38): 40799–814, CrossRef.
Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo JY, et al. Feedback loop regulation of SCAP/SREBP-1 by miR-29 modulates EGFR signaling-driven glioblastoma growth. Cell Rep. 2016; 16(6): 1527–35, CrossRef.
Lu G, Wu X, Zhao Z, Ding Y, Wang P, Wu C, et al. MicroRNA-126 regulates the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathway in SLK cells in vitro and the expression of its pathway members in Kaposi’s sarcoma tissue. Medicine (Baltimore). 2018; 97(35): e11855, CrossRef.
Tu J, Cheung HH, Lu G, Chan CLK, Chen Z, Chan WY. microRNA-126 is a tumor suppressor of granulosa cell tumor mediated by its host gene EGFL7. Front. Oncol. 2019; 9: 486, CrossRef.
Javed MR, Sadaf M, Ahmed T, Jamil A, Nawaz M, Abbas H, et al. CRISPR-Cas system: history and prospects as a genome editing tool in microorganisms. Curr Microbiol. 2018; 75(12): 1675–83, CrossRef.
Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9. FEBS J. 2014; 281(23): 5186–93, CrossRef.
Bender G, Fahrioglu Yamaci R, Taneri B. CRISPR and KRAS: a match yet to be made. J Biomed Sci. 2021; 28: 77, CrossRef.
DOI: https://doi.org/10.18585/inabj.v14i1.1824
Copyright (c) 2022 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
